Niveles de actividad enzimática de paraoxonasa 1 en pacientes con demencia tipo Alzheimer y demencia vascular
Contenido principal del artículo
Resumen
La paraoxonasa (PON1) es una enzima antioxidante que puede reducir la oxidación de la LDL. Los polimorfismos que codifican los genes de la paraoxonasa son factores de riesgo establecidos en una variedad de trastornos vasculares como la enfermedad arterial coronaria y la estenosis de la arteria carótida, pero su asociación con la EA es controversial.
Detalles del artículo
Sección
Cómo citar
Referencias
10/66 Dementia Research Group. Care arrangements for people with dementia in developing countries. Int J Geriatr Psychiatry 2004;
: 170-7.
Patel V, Prince M. Ageing and mental health in a developing country: who cares? Qualitative studies from Goa, India. Psychol Med 2001;
: 29-38.
Ferri CP, Prince M, Brayne C. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-17.
Morris JC. Dementia Update. 2005. Alzheimer Dis Assoc Disord 2005; 19: 100-17.
Larson EB, Shadlen MF, Wang L, et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 2004; 140: 105-9.
Swanson KA, Carnahan RM. Dementia and Comorbidities: an overview of diagnosis and management. J Pharmac Practic 2007 20; 4: 296-317.
Zanni GR, Wick JY. Differentiating dementias in long-term care patients. Consult Pharm 2007; 22: 14-28.
Corder EH, Saunders AM, Strittmatter WJ, et al. Glue dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-5.
Liddell M, Williams J, Bayer A, et al. Confirmation of association between the E4 allele of apolipoprotein E and Alzheimer's disease. J Med Genet 1994; 31: 197-200.
Palumbo B, Parnetti L, Nocentini G, et al. Apolipoprotein E genotype in normal aging, age-associated memory impairment, Alzheimer's disease and vascular dementia patients. Neuroscience Letters 1997; 231: 59-61.
Morris JC. Handbook of Dementing Illnesses. New York, NY; Marcel Dekker Inc; Ed.; 1994, p. 92-7.
Buée L, Bussiére T, Buée-Scherrer V. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 2000;
: 95-130.
Kondinor AR, Berezov TT, Kondinova NA. Alzheimer's amyloid beta and lipid metabolism: a missing link? FASEB-J 1998; 12: 1097-9.
Bétard C, Robitaille Y, Gee M, et al. Apo E allele frequencies in Alzheimer's disease, Lewy body dementia, Alzheimer's disease with cerebrovascular disease and vascular dementia. Neuro Report 1994;5: 1893-6.
Behl C, Davis J. Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem 1992; 186: 944-50.
Dyrks T, Dyrks E. Amyloidogenicity of beta A amyloid. J Biol Chem 1992; 267: 18210-17.
Troncoso J, Costello A, Watson AL Jr. In vitro polymerization of oxidized tau into filaments. Brain Res 1993; 613: 313-16.
Ross R. Cellular and molecular studies of atherogenesis. Atherosclerosis 1997; 13(Suppl.): 53-4.
Vinters HV, Ellis WG, Zarow C, Zaias BW, Jagust WJ, Mack WJ, Chui HC: Neuropathologic substrates of ischaemic vascular dementia. J Neuropathol Exp Neurol 2000; 59: 931-45.